Finance

Lists
Why is 6160 up 4,36%?
Dive Deeper
6160:HKG
BeOne Medicines AG
225,00 HKD
+4,36%
(+9,40) 1D
16 ოქტ, 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 6160...
Open
224,80 HKD
High
230,20 HKD
Low
221,80 HKD
Mkt. cap
355,76 მლრ.
Avg. vol.
2,93 მლნ.
Volume
4,41 მლნ.
P/E ratio
65,67
52-wk high
235,60 HKD
52-wk low
153,00 HKD
EPS
3,43 HKD
Shares outstanding
1,43 მლრდ.
No. of employees
12 ათ.
Open
224,80 HKD
High
230,20 HKD
Low
221,80 HKD
Mkt. cap
355,76 მლრ.
Avg. vol.
2,93 მლნ.
Volume
4,41 მლნ.
P/E ratio
65,67
52-wk high
235,60 HKD
52-wk low
153,00 HKD
EPS
3,43 HKD
Shares outstanding
1,43 მლრდ.
No. of employees
12 ათ.
News stories
From web sources and news partners
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOჯონ ვინსენტ ოილერი | ჯონ ვინსენტ ოილერი
Employees12 ათ.
Founded28 ოქტ. 2010
Headquarters-
Sector-
Websitebeonemedicines.com
Last report
5 აგვ. 2026
Fiscal period
Q2 2026
2,05 US$ / 1,63 US$
+25,66%beat
Revenue / Est. (USD)
1,71 მლრდ. / 1,62 მლრდ.
+5,33%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,41 მლრდ.
1,50 მლრდ.
1,51 მლრდ.
1,71 მლრდ.
Cost of goods sold
196,51 მლნ.
142,42 მლნ.
167,22 მლნ.
174,53 მლნ.
Cost of revenue
196,51 მლნ.
142,42 მლნ.
167,22 მლნ.
174,53 მლნ.
Research and development expenses
523,66 მლნ.
615,42 მლნ.
541,22 მლნ.
612,28 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
529,00 მლნ.
555,29 მლნ.
555,10 მლნ.
593,21 მლნ.
Operating expense
1,05 მლრდ.
1,17 მლრდ.
1,10 მლრდ.
1,21 მლრდ.
Total operating expenses
1,25 მლრდ.
1,31 მლრდ.
1,26 მლრდ.
1,38 მლრდ.
Operating income
163,11 მლნ.
185,04 მლნ.
249,90 მლნ.
325,05 მლნ.
Other non operating income
-4,76 მლნ.
4,16 მლნ.
14,54 მლნ.
-2,68 მლნ.
EBT including unusual items
147,16 მლნ.
149,24 მლნ.
259,22 მლნ.
312,46 მლნ.
EBT excluding unusual items
160,80 მლნ.
189,96 მლნ.
259,22 მლნ.
309,33 მლნ.
Income tax expense
22,32 მლნ.
82,74 მლნ.
31,86 მლნ.
75,45 მლნ.
Effective tax rate
15,17%
55,44%
12,29%
24,15%
Other operating expenses
-
-
-
-
Net income
124,84 მლნ.
66,50 მლნ.
227,36 მლნ.
237,01 მლნ.
Net profit margin
8,84%
4,44%
15,02%
13,90%
Earnings per share
1,09
0,58
1,96
2,05
Interest and investment income
13,79 მლნ.
32,37 მლნ.
27,66 მლნ.
27,90 მლნ.
Interest expense
-10,76 მლნ.
-32,47 მლნ.
-32,89 მლნ.
-39,74 მლნ.
Net interest expenses
3,03 მლნ.
-103,00 ათ.
-5,22 მლნ.
-11,84 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
198,86 მლნ.
219,47 მლნ.
289,30 მლნ.
363,97 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები